Study of AK112 in the Treatment of Advanced Gynecological Tumors
A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.
Gynecologic Cancer|Cancer Metastatic|Ovarian Neoplasms|Cervical Neoplasm|Endometrial Neoplasms
DRUG: AK112
Objective response rates (ORR) according to RECIST v1.1 in the FAS population, Up to approximately 2 years
Efficacy endpoint: disease control rate (DCR) assessed according to RECIST v1.1, Up to approximately 2 years|Efficacy endpoint: duration of response (DOR) assessed according to RECIST v1.1, Up to approximately 2 years|Efficacy endpoint: time to response (TTR) assessed according to RECIST v1.1, Up to approximately 2 years|Efficacy endpoint: progression-free survival (PFS) assessed according to RECIST v1.1, Up to approximately 2 years|Efficacy endpoint: overall survival (OS) assessed according to RECIST v1.1, Up to approximately 2 years|Serum PK concentrations of AK112 in individual subjects at different time points after AK112 administration, Up to approximately 2 years|Number of subjects with detectable anti-drug antibodies (ADA), Up to approximately 2 years|Percentage of subjects with detectable anti-drug antibodies (ADA), Up to approximately 2 years|Correlation between the expression of PD-L1 and the antitumor activity of AK112 in tumor tissues, Up to approximately 2 years|Correlation between microsatellite instability (MSI) and mismatch repair defect (DMMR) in tumor tissue samples from patients with endometrial cancer and the antitumor activity of AK112, Up to approximately 2 years|The association between BRCA1/2 mutation and AK112 antitumor activity in peripheral blood samples and tumor tissues from patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, Up to approximately 2 years
A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.